Fulcrum Therapeutics Inc (NASDAQ:FULC) Q1 2020 Earnings Conference Call - Final Transcript

May 13, 2020 • 08:00 am ET


Fulcrum Therapeutics Inc (NASDAQ:FULC) Q1 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning and welcome to Fulcrum Therapeutics First Quarter 2020 Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call over to Christi Waarich, Director of Investor Relations and Corporate Communications at Fulcrum. Please proceed.

Christi Waarich

Thank you, Demetria. Good morning and welcome to the Fulcrum Therapeutics conference call to discuss our first quarter 2020 financial results and recent corporate highlights. Earlier today, we issued a press release outlining our recent progress. For those of you who don't have a copy, you can access it in the investor relations section of our website at fulcrumtx.com. Please be reminded that remarks made during this call may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development timelines, and financial projections.

While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business. With me on today's call are Robert Gould, President and Chief Executive Officer; Diego Cadavid, Senior Vice President of Clinical Development; Owen Wallace, Chief Scientific Officer and Bryan Stuart, Chief Operating Officer. Let me quickly run through this morning's agenda.

Robert will begin the call with an overview of our recent progress. Diego will discuss our FSHD program. Owen will discuss our sickle cell program and research efforts and Brian will cover our financials before opening the call for Q&A. With that, it's my pleasure to turn the call over to Robert. Robert?

Robert Gould

Thank You, Christi. Good morning, everyone and thank you for joining us today. I first want to thank the healthcare workers, investigators, and caregivers for their courage and compassion as they continue to support so many during the challenges of COVID-19. Our hearts go out to everyone who has been impacted; to all of our friends, colleagues, and the patient communities we serve, we hope you are keeping safe and healthy. Fulcrum's mission and purpose remain unchanged as we work to discover and develop therapeutics to treat genetically defined diseases by addressing their root cause. I'm proud of how our employees have risen to the evolving challenges of the COVID-19 pandemic.

I'd like to begin by highlighting some of our recent updates and accomplishments. Today, we announced an amendment to ReDUX4, our Phase 2b trial with losmapimod in patients with facioscapulohumeral muscular dystrophy or FSHD. Diego will go over the amendment in more detail. These changes will extend the patient treatment from the original trial design and we believe will provide a more robust data set while addressing the challenges presented by COVID-19. Early in